Lowenstein Sandler represented Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, in a $22 million underwritten public offering of shares and warrants that closed on May 5, 2020.

Notably, in connection with the offering, Delcath’s common stock was approved for listing on the Nasdaq Capital Market and began trading on the Nasdaq Capital Market under the symbol “DCTH” on May 1, 2020.

The Lowenstein Sandler deal team included John D. "Jack" Hogoboom, Robert J. Paradiso, Brian A. Silikovitz, James C. Shehan, Sarah P. Cole, Michael T. Melchiorre, Erica Perlmutter, and Kristin V. Taylor.